Table 2

Outcomes evaluated with cardiac MRI

Full analysis set set (n=169)P values
Danegaptide high (n=57)Danegaptide low (n=60)Placebo (n=52)
CMR AAR (%LV)35.6±10.837.4±11.439.2±13.80.333
CMR AAR (g)54.7±24.355.4±21.564.4±40.00.460
Acute infarct size (%LV)21.7±10.621.2±9.724.2±13.00.575
Acute infarct size (g)33.5±20.433.5±20.433.5±20.40.416
Final infarct size (%LV)14.0±7.113.7±6.715.4±7.70.950
Final infarct size (g)19.6±11.418.6±9.621.4±15.00.880
Presence of MVO40 (72.7)39 (67.2)37 (72.5)0.638
LVEF 90 days (%)53.9±9.552.7±10.352.1±10.90.638
Modified APPROACH score26.8±11.027.7±11.430.4±11.40.147
Variant MSI42.2±33.945.4±28.545.7±33.60.637
  • Data are presented as mean±SD or n (%).

  • MSI calculated as: (CMR AAR (g) – final infart size (g))/CMR AAR (g).

  • Variant MSI calculated as: (modified APPROACH (%) – final infarct size (%))/modified APPROACH (%).

  • P value derived from the Kruskal-Wallis non-parametric test excluding one extreme outlier.

  • AAR, area at risk; CMR, cardiac MRI; LV, left ventricle; LVEF, left ventricular ejection fraction; MSI, myocardial salvage index; MVO, Micro Vascular Obstruction.